PER® Winter Lung Cancer Conference
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Related Articles
Cellular Therapies and Novel Targeted Agents Will Shape the Future of R/R ALL Management
Marlise Luskin, MD, MSCE, discusses the treatment paradigm for relapsed/refractory ALL and research seeking to integrate agents into the frontline setting
Dr Shields on Key ADRIATIC Trial Data With Adjuvant Durvalumab in LS-SCLC
Misty D. Shields, MD, PhD, discusses the implications of the ADRIATIC trial of adjuvant therapy with durvalumab vs placebo in patients with LS-SCLC.
Tisotumab Vedotin Boosts Survival in Chinese Subpopulation With Previously Treated Cervical Cancer
Tisotumab vedotin led to improved survival vs chemotherapy in a Chinese subpopulation of previously treated cervical cancer enrolled in innovaTV 301.
Dr Lee on Real-World Early Outcomes With Second-Line Axi-Cel for R/R LBCL
Dasom (Caroline) Lee, MD, discusses real-world early outcomes of treatment with second-line axi-cel in relapsed/refractory large B-cell lymphoma.
Dr Langer on the Evolution of Adjuvant Immunotherapy in NSCLC
Corey J. Langer, MD, discusses how the use of adjuvant immunotherapy has affected the resectable NSCLC treatment paradigm.
PER® Winter Lung Cancer Conference
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
ADC Development in Ovarian Cancer: What’s Next for FRa and Beyond?
Kathleen Moore, MD, MD, FASCO, discusses the development of antibody-drug conjugates in ovarian cancer and how they could shift the field.
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Dr. David S. Hong presents the preliminary Phase 1 results on RMC-9805, a first-in-class, oral, RAS(ON) G12D-selective inhibitor, highlighting its promising safety, pharmacokinetics, and early…
Dr Naumann on Next-Generation Antibody-Drug Conjugates in Ovarian Cancer
R. Wendel Naumann, MD, discusses next-generation antibody-drug conjugates in ovarian cancer.
Dr Lheureux on the Evolution of ADCs Since Mirvetuximab Soravtansine in Ovarian Cancer
Stéphanie Lheureux, MD, PhD, discusses the evolution of antibody-drug conjugates since mirvetuximab soravtansine in ovarian cancer.